Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
Globe Newswire (Thu, 8-Oct 7:00 AM ET)
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
Globe Newswire (Tue, 29-Sep 7:00 AM ET)
Globe Newswire (Thu, 20-Aug 7:00 AM ET)
Globe Newswire (Wed, 12-Aug 7:00 AM ET)
Globe Newswire (Tue, 4-Aug 7:00 AM ET)
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
Globe Newswire (Wed, 29-Jul 7:00 AM ET)
Globe Newswire (Tue, 21-Jul 7:00 AM ET)
Aclarion Targets Payer Expansion and CLARITY Trial Milestones as CEO Outlines Strategic 2026 Vision
Market Chameleon (Fri, 20-Mar 6:58 AM ET)
Aclarion Achieves 114% Surge in Q4 Nociscan Volumes and Extends Cash Runway Into 2027
Market Chameleon (Thu, 8-Jan 2:05 AM ET)
Market Chameleon (Mon, 13-Oct 7:44 AM ET)
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
Aclarion trades on the NASDAQ stock market under the symbol ACON.
As of October 12, 2026, ACON stock price declined to $2.24 with 26,900 million shares trading.
ACON has a beta of -0.02, meaning it tends to be less sensitive to market movements. ACON has a correlation of 0.00 to the broad based SPY ETF.
ACON has a market cap of $6.47 million. This is considered a Sub-Micro Cap stock.
Last quarter Aclarion reported $25,208 in Revenue and -$1.12 earnings per share. This fell short of revenue expectation by $-4,792 and missed earnings estimates by -$.07.
In the last 3 years, ACON traded as high as $89,552.56 and as low as $1.95.
The top ETF exchange traded funds that ACON belongs to (by Net Assets): VXF.
ACON has underperformed the market in the last year with a price return of -73.4% while the SPY ETF gained +17.1%. ACON has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.9% and -13.3%, respectively, while the SPY returned +3.8% and +0.9%, respectively.
ACON support price is $2.21 and resistance is $2.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACON shares will trade within this expected range on the day.
